Heron Therapeutics' (HRTX) Price Target Raised to $54 at BofA/Merrill Lynch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Brean Capital Raises Price Target on Heron Therapeutics (HRTX) Following Positive HTX-011 Results
September 23, 2015 11:00 AM EDTBrean Capital reiterated a Buy rating on Heron Therapeutics (NASDAQ: HRTX), and raised the price target to $55.00 (from $45.00), following announced positive top-line results from HTX-011. Analyst Jonathan Aschoff projects HTX-011 to have a higher price, and drive significant value.
Aschoff commented, "Yesterday, Heron announced positive top-line results from its Phase 2 trial of HTX-011 for the treatment of post-operative pain after bunionectomy. This randomized, placebo-controlled, double-blind, Phase 2 trial evaluated the... More
Leerink Boosts PT on Heron Therapeutics (HRTX) to $57 Following HTX-011 Phase 2 Top-Line Results
September 23, 2015 6:50 AM EDTLeerink lifts its price target on Outperform-rated Heron Therapeutics (Nasdaq: HRTX) from $38 to $57 after the company announced positive, top-line results from its Phase 2 clinical study of HTX-011 in the management of post-operative pain in patients undergoing bunionectomy.
Analyst Jason Gerberry commented, HRTX... More
Heron Therapeutics (HRTX) PT Lifted to $58 at Jefferies Following Positive Data
September 23, 2015 6:46 AM EDTJefferies analyst Biren Amin reiterated a Buy rating and boosted his price target on Heron Therapeutics (NASDAQ: HRTX) to $58.00 (from $47.00) after the company reported positive data evaluating HTX-011 in the PII bunionectomy trial, which showed reductions in pain intensity v. pbo over 24 hrs (-69%), 48... More
Heron Therapeutics (HRTX) Announces HTX-011 Phase 2 Met Primary, Secondary Endpoints in Post-Operative Pain
September 22, 2015 4:07 PM EDTHeron Therapeutics (NASDAQ: HRTX) announced positive, top-line results from its Phase 2 clinical study of HTX-011 in the management of post-operative pain in patients undergoing bunionectomy. HTX-011, which utilizes Herons proprietary Biochronomer® drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the... More
Heron Therapeutics (HRTX) Announces Top-Line Results From Phase 2 Study of HTX-011 in Post-Operative Pain
September 22, 2015 4:06 PM EDTHeron Therapeutics (NASDAQ: HRTX) today announced positive, top-line results from its Phase 2 clinical study of HTX-011 in the management of post-operative pain in patients undergoing bunionectomy. HTX-011, which utilizes Herons proprietary Biochronomer® drug delivery... More
